#China #Shanghai #DualityBio #NMPA #Trastuzumab Pamirtecan

Overview of DualityBio's Milestone

DualityBio, a clinical-stage biotechnology company, announced a significant advancement with the acceptance of its Biologics License Application (BLA) by the National Medical Products Administration (NMPA) of China. This application is for its investigational antibody-drug conjugate, trastuzumab pamirtecan (also known as T-Pam or DB-1303), aimed at providing a new treatment option for adult patients suffering from unresectable or metastatic HER2-positive breast cancer. This milestone is not only crucial for the company but also represents a potential breakthrough in the treatment of a common cancer type.

The Application and Its Significance

The BLA acceptance by the NMPA is based on preliminary positive results from the pivotal Phase III clinical trial, DB-1303-O-3001. This multicenter, randomized, open-label study was conducted in China to evaluate the efficacy and safety of trastuzumab pamirtecan in comparison to trastuzumab emtansine (T-DM1) in patients who had previously been treated with chemotherapy containing trastuzumab and taxanes.

The independent data monitoring committee found that T-Pam achieved a statistically significant improvement in progression-free survival compared to T-DM1, marking a promising advance in treatment protocols for this difficult-to-treat cancer. With over 350,000 new cases of breast cancer reported in China annually, the need for effective therapies is urgent.

Collaboration for Market Strategy

Dr. Hua Mu, Chief Medical Officer at DualityBio, highlighted the significance of this development. Given the high incidence of breast cancer in China, the company has also formed a partnership with 3SBio to facilitate the commercialization of trastuzumab pamirtecan across mainland China, Hong Kong, and Macao. This collaboration aims to ensure that patients receive timely access to this new therapeutic option.

Moreover, DualityBio intends to enhance its global strategy by deepening its alliance with BioNTech, focusing on developing and marketing the product worldwide. By leveraging these strategic partnerships, the company expects to maximize the clinical value of T-Pam and extend treatment options for patients with diverse cancer profiles.

About Trastuzumab Pamirtecan

Trastuzumab pamirtecan is a third-generation antibody-drug conjugate that utilizes a topoisomerase-1 inhibitor targeting HER2, developed collaboratively by DualityBio and BioNTech. The drug was designed using DualityBio’s proprietary technology platform, the Duality Immune Toxin Antibody Conjugates (DITAC). HER2, a protein expressed on the surface of solid tumors, is involved in aggressive tumor growth and cancer cell spread, making it a potential target for innovative oncological therapies.

The therapeutic has demonstrated antitumor activity in both HER2-positive and low HER2-expressing tumor models, showcasing its versatility in treating various solid tumors, including breast and endometrial cancers. Preliminary clinical and preclinical data suggest that trastuzumab pamirtecan effectively targets HER2 receptors regardless of the expression level, presenting a manageable safety profile and the potential for an expanded therapeutic window.

Ongoing Clinical Trials

Currently, trastuzumab pamirtecan is under investigation in several global trials focusing on different solid tumors and novel treatment combinations. Notably, the drug has received Fast Track Designation and Innovative Therapy Designation from the U.S. FDA for endometrial cancer treatment in 2023. Trials include pivotal studies addressing first-line treatment in metastatic HER2-low breast cancer and second-line therapy in endometrial cancer, among others.

Conclusion

As DualityBio advances its application for trastuzumab pamirtecan through regulatory reviews and strategic collaborations, the company stands poised to make a significant impact in the landscape of treatments available for breast cancer and potentially other malignancies. The ongoing efforts signal hope for improved clinical outcomes and enhanced quality of life for patients battling these challenging conditions.